| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 16200601 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 403 journal articles in the PubMed database | Email to a friend | | |
| Mease PJ, Gladman DD, Ritchlin CT, et al.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Arthritis Rheum 2005 Oct; 52(10):3279-89.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gladman DD, Mease PJ, Ritchlin CT, et al.
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. [Journal Article, Research Support, Non-U.S. Gov't]
Arthritis Rheum 2007 Feb; 56(2):476-88.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Keystone EC, Kavanaugh AF, Sharp JT, et al.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Arthritis Rheum 2004 May; 50(5):1400-11.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Genovese MC, Mease PJ, Thomson GT, et al.
Safety and Efficacy of Adalimumab in Treatment of Patients with Psoriatic Arthritis Who Had Failed Disease Modifying Antirheumatic Drug Therapy. [JOURNAL ARTICLE]
J Rheumatol 2007 Apr 15.
Abstract | Full Citation | Find Related Articles | | Weisman MH, Moreland LW, Furst DE, et al.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. [Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial]
Clin Ther 2003 Jun; 25(6):1700-21.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Antoni CE, Kavanaugh A, Kirkham B, et al.
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Arthritis Rheum 2005 Apr; 52(4):1227-36.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Furst DE, Schiff MH, Fleischmann RM, et al.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). [Clinical Trial, Journal Article, Randomized Controlled Trial]
J Rheumatol 2003 Dec; 30(12):2563-71.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Weinblatt ME, Keystone EC, Furst DE, et al.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Arthritis Rheum 2003 Jan; 48(1):35-45.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Gladman DD, Mease PJ, Cifaldi MA, et al.
Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: Patient- reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). [JOURNAL ARTICLE]
Ann Rheum Dis 2006 Oct 17.
Abstract | Full Citation |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
